Plaque Reduction Assay
Measures the extent to which various concentrations of acyclovir inhibit the growth of virus in cell culture. The concentration of drug which results in a 50% reduction in plaque formation induced by viral cytopathic effect (CPE) versus the no-drug control establishes an inhibitory dose (ID-50) drug concentration reportable value.
17 - 28 days
- Zovirax Resistance
- HSV Types 1/2 Phenotyping for Acyclovir Drug Resistance
- Acyclovir Resistance HSV (Phenotype)
- Herpes Simplex Virus (HSV) Types 1 & 2 Phenotyping for Acyclovir Resistance
Acceptable sites for swab collection include: eye, genital,oral, urethral, vesicle or throat. Refrigerate
Test sent to Mayo Medical Laboratories; performed by LabCorp Burlington.